e-learning
resources
Vienna 2012
Sunday, 02.09.2012
Inflammatory mechanisms in COPD
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Differences in cellular expression of C-reactive protein and serum amyloid A in lung tissue in patients with chronic obstructive pulmonary disease
C. Calero, E. Arellano, A. Montes-Worboys, V. Sanchez, D. Tobar, N. Moreno, E. Barrot, J.L. Lopez-Campos (Seville, Madrid, Spain)
Source:
Annual Congress 2012 - Inflammatory mechanisms in COPD
Session:
Inflammatory mechanisms in COPD
Session type:
Thematic Poster Session
Number:
792
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
C. Calero, E. Arellano, A. Montes-Worboys, V. Sanchez, D. Tobar, N. Moreno, E. Barrot, J.L. Lopez-Campos (Seville, Madrid, Spain). Differences in cellular expression of C-reactive protein and serum amyloid A in lung tissue in patients with chronic obstructive pulmonary disease. Eur Respir J 2012; 40: Suppl. 56, 792
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Evidence-based eHealth for COPD
Related content which might interest you:
C-reactive protein and serum amyloid A overexpression in lung tissues of chronic obstructive pulmonary disease patients
Source: Annual Congress 2012 - Inflammatory mechanisms in COPD
Year: 2012
Factors affecting C-reactive protein levels in patients with chronic obstructive pulmonary disease
Source: Annual Congress 2007 - Different aspects of COPD exacerbations
Year: 2007
C-reactive protein levels and clinically important predictive outcomes in stable COPD patients
Source: Eur Respir J 2006; 27: 902-907
Year: 2006
The value of C-reactive protein as a marker of systemic inflammation in stable chronic obstructive pulmonary disease
Source: Eur Respir J 2007; 30: Suppl. 51, 363s
Year: 2007
Serum amyloid A in patients with stable chronic obstructive pulmonary disease
Source: International Congress 2018 – Clinical determinants and biomarkers of COPD
Year: 2018
Body composition and plasma levels of inflammatory biomarkers in COPD
Source: Eur Respir J 2010; 36: 1027-1033
Year: 2010
Genetically elevated C-reactive protein and chronic obstructive pulmonary disease
Source: Annual Congress 2009 - Environmental and genetic risk factors for asthma and COPD
Year: 2009
Serum leptin levels in patients with chronic obstructive pulmonary disease
Source: Eur Respir J 2002; 20: Suppl. 38, 259s
Year: 2002
Comparison of serum osteopontin levels in patients with exacerbations and stable chronic obstructive pulmonary disease
Source: Annual Congress 2012 - Cell biology, blood and sputum biomarkers in airway diseases
Year: 2012
Increased CCL18 serum levels in patients with pulmonary fibrosis which reflect disease severity
Source: Eur Respir J 2005; 26: Suppl. 49, 21s
Year: 2005
Relationship between circulating thrombomodulin levels and latent progression of atherosclerosis in patients with chronic obstructive pulmonary disease
Source: Annual Congress 2008 - Pulmonary vascular disease and other pulmonary conditions: miscellaneous
Year: 2008
C-reactive protein in pulmonary tuberculosis-correlation with extent and severity of the disease
Source: Annual Congress 2012 - Tuberculosis: clinical findings II
Year: 2012
Overexpression of chitotriosidase and YKL-40 in serum and sputum in healthy smokers and patients with chronic obstructive pulmonary disease
Source: International Congress 2018 – Clinical determinants and biomarkers of COPD
Year: 2018
Circulating fibronectin to C-reactive protein ratio and mortality: a biomarker in COPD?
Source: Eur Respir J 2008; 32: 1451-1457
Year: 2008
Late Breaking Abstract - Increased serum levels of YKL-40 in male smoking chronic obstructive pulmonary disease patients associated with altered miRNA levels in alveolar macrophages
Source: Virtual Congress 2020 – New biomarkers for management of obstructive diseases
Year: 2020
Neutrophil elastase levels is higher in patients with lung cancer than chronic obstructive pulmonary disease
Source: Annual Congress 2011 - Biomarkers and other new methods for lung cancer
Year: 2011
Serum magnesium levels of patients with chronic obstructive pulmonary disease
Source: Eur Respir J 2003; 22: Suppl. 45, 107s
Year: 2003
Evaluation of neutrophil lymphocyte ratio and C-reactive protein values in the treatment of acute chronic obstructive pulmonary disease exacerbation according to endotype
Source: Virtual Congress 2020 – Monitoring of patients with COPD
Year: 2020
Elevated serum LOXL2 levels are associated with rapid disease progression in idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis
Year: 2012
Serum progranulin levels in idiopathic pulmonary fibrosis and other interstitial lung diseases
Source: International Congress 2018 – Idiopathic interstital pneumonias other than idiopathic pulmonary fibrosis (IPF)
Year: 2018
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept